邢成文,侯 明,李玉鹏,蒲应香,李鹏业.噻托溴铵联合沙美特罗治疗慢性阻塞性肺疾病的临床效果[J].现代生物医学进展英文版,2017,17(15):2957-2960. |
噻托溴铵联合沙美特罗治疗慢性阻塞性肺疾病的临床效果 |
Effect of Tiotropium Combined with Salmeterol in the Treatment of Chronic Obstructive Pulmonary Disease |
Received:September 22, 2016 Revised:October 21, 2016 |
DOI:10.13241/j.cnki.pmb.2017.15.041 |
中文关键词: 噻托溴铵 沙美特罗 慢性阻塞性肺疾病 临床效果 |
英文关键词: Tiotropium Salmeterol Chronic obstructive pulmonary disease Clinical effect |
基金项目: |
|
Hits: 306 |
Download times: 144 |
中文摘要: |
摘要 目的:探讨噻托溴铵联合沙美特罗治疗慢性阻塞性肺疾病的临床效果。方法:选取我院2008年8月~2016年8月期间收治的68例慢性阻塞性肺疾病患者,由电脑随机均分为两组,每组34例,其中对照组给予沙美特罗进行治疗,而观察组在此基础上施加噻托溴铵治疗。对比观察两组患者治疗前后肺功能指标的变化、运动能力、生活质量、预后及不良事件发生率。结果:治疗前,两组患者的肺功能各项指标、6分钟步行距离(6MWD)和圣乔治呼吸问卷(SGRQ)评分均无明显差异(P>0.05)。治疗后均较治疗前有明显改善,且观察组同期改善程度均显著高于对照组(P<0.05)。观察组在治疗后12个月内发生急性加重的例数明显少于对照组(P<0.05),且不良事件发生率明显低于对照组(P<0.05)。结论:联合使用噻托溴铵与沙美特罗治疗慢性阻塞性肺疾病,可更好地改善患者的肺功能、运动能力及生活质量,且急性加重率和不良事件发生率更低,值得进一步推广与应用。 |
英文摘要: |
ABSTRACT Objective: To investigate the effects of combining tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease. Methods: 68 cases of chronic obstructive pulmonary disease in our hospital were selected from August 2008 to Au- gust 2016. All the patients were randomly divided into two groups, 34 cases in each group. The control group was treated with Salme- terol, while the observation group was treated with the Tiotropium based on the control group. The changes of pulmonary function, exer- cise capacity, quality of life, prognosis and adverse events were compared between the two groups before and after treatment. Results: Before treatment, there were no significant differences in lung function indexes, 6 minutes walk distance (6MWD) and St. George's Res- piratory Questionnaire (SGRQ) scores in the two groups (P>0.05). After treatment, the pulmonary function index, 6MWD and SGRQ score of the two groups were significantly improved. And the improvement degree of lung function indexes, 6MWD and SGRQ scores in the same period of observation group was significantly higher than that in control group (P<0.05). In addition, the patients with acute ex- acerbation in the observation group were significantly less than the control group (P<0.05) within 12 months after treatment, and the inci- dence of adverse events was significantly lower than that of the control group (P<0.05). Conclusion: Tiotropium combined with Salme- terol can significantly improve the pulmonary function, exercise capacity, quality of life of patients in the treatment of chronic obstructive pulmonary disease, and the combined curative effect is superior to Salmeterol monotherapy with less adverse events, so it is worthy of further promotion and application. |
View Full Text
View/Add Comment Download reader |
Close |